<DOC>
	<DOCNO>NCT02718911</DOCNO>
	<brief_summary>The main purpose study evaluate safety colony-stimulating factor 1 receptor ( CSF-1R ) inhibitor LY3022855 combination durvalumab tremelimumab participant advance solid tumor .</brief_summary>
	<brief_title>A Study LY3022855 Combination With Durvalumab Tremelimumab Participants With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>Must histological cytological evidence diagnosis cancer amenable curative therapy . Part B : Must type malignancy study . Part A Part B : Must willing undergo pretreatment ontreatment core needle excisional tumor biopsy . Part A ( cohort ) : Have presence measureable /or nonmeasurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 . Part B ( cohort ) : Have presence measurable disease define RECIST 1.1 . Have adequate normal organ marrow function , include follow : Absolute neutrophil count ≥ 1.5 x 10⁹/Liters ( L ) ( 1500/cubic millimeter ) Platelet count ≥ 100 x 10⁹/L ( ≥100,000/cubic millimeter ) Hemoglobin ≥9 gram per deciliter ≥5.6 millimoles per liter Serum Creatinine ≤1.5 × institutional upper limit normal ( ULN ) Total bilirubin ≤1.5 × institutional ULN Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5 × institutional ULN OR ≤5 × institutional ULN participant liver metastases International normalized ratio ( INR ) prothrombin time ( PT ) INR ≤1.5 × institutional ULN PT ≤5 second institutional ULN PTT activate partial thromboplastin time ( aPTT ) ≤5 second institutional ULN Thyroid stimulate hormone ( TSH ) OR free thyroxine ( T4 ) within normal limit Have performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale . Are currently receive prior use immunosuppressive medication within 28 day first dose study drug , exception intranasal inhaled corticosteroid systemic corticosteroid physiological dos , exceed 10 milligrams/day prednisone , equivalent corticosteroid . Have symptomatic central nervous system ( CNS ) malignancy metastasis . Have prior Grade ≥3 immunerelated adverse event ( irAE ) receive previous immunotherapy agent , unresolved irAE Grade &gt; 1 , irAE lead permanent discontinuation prior immunotherapy . Have experience Grade ≥3 AE neurologic ocular AE grade receive prior immunotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>